Oricell Therapeutics Announces $70 Million Series C1 Financing to Advance Global Clinical Development of Innovative CAR-T Therapies

Jan 12, 2026 08:34 CST Updated 08:34

Oricell Therapeutics

Developer of Tumor Immunocyte Products

January 12, 2026QrigincellTherapeutics（Oricell Therapeutics Holdings Limited) announced the completion of a $70 million Series C1 financing round. This round was led by Beijing Municipal Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund, with participation from QIA (Qatar Investment Authority), NGS (Australian Superannuation Fund), Yizhuang Guotou, Licheng Investment, Ruifeng Capital, and other institutions.

As an innovative pioneer in the field of cell therapy drugs, Qrigincell Therapeutics has always been committed to developing CAR-T cell therapies with global clinical value, and has generated proof-of-concept (POC) clinical data from multiple pipelines. Oricell, relying on its self-innovated Ori®Ab antibody screening and engineering platform, Ori®Armoring structure platform, and OnGo(Fast)CMC process expertise, is capturing the global CAR-T technology high ground with differentiated pipelines.

Ori-C101, developed by Qrigincell Therapeutics, is an autologous CAR-T drug targeting GPC3 for the treatment of advanced hepatocellular carcinoma (HCC). It has completed Phase I investigator-initiated clinical studies and Phase I registered clinical trials, and is about to commence pivotal Phase II clinical trials. The available clinical data demonstrates excellent efficacy and safety, and has been presented multiple times at top international academic conferences such as ASCO. This product is expected to become the world's first approved CAR-T drug for hepatocellular carcinoma.

At the same time, Qrigincell Therapeutics' full platform is giving rise to multiple next-generation multi-target and multi-mechanism CAR-T products. Its innovative secretory CAR-T, OriC902, has achieved breakthrough efficacy in end-stage solid tumor patients. The company’s self-developed dual-target in vivo CAR-T product has initiated exploratory clinical research, demonstrating the technical potential of "off-the-shelf CAR-T" – generating CAR-T cells directly within the patient's body, greatly enhancing the accessibility of cell-based therapies.

This USD financing will accelerate Qrigincell Therapeutics' internationalization and clinical development process, strengthen its technical capabilities in the cell therapy field, and enhance the value of its industrialization pipeline.

Co-Founder and CEO of Qrigincell TherapeuticsDr. Huanfeng YangRepresentation"Very grateful for the investors' recognition of the company. The company will continue to focus on the global clinical advancement of its core pipeline, in vivo products, and cutting-edge technology R&D. Leveraging the company's profound technical expertise and current opportunities in policy and market environments, we will accelerate the development of clinical-stage products. With more breakthrough cell therapy solutions, we aim to bring new hope of cure to cancer patients worldwide and steadily progress towards becoming a global leader in immune-oncology."

Mr. Peng Ren, Chairman and General Manager of Beijing Shunxi Private Fund Management Co., Ltd.Representation："We believe that cell therapy is an important direction for conquering solid tumors, and the clinical progress of QrigincellTherapeutics' GPC3 CAR-T in treating liver cancer has surprised us greatly. We highly recognize the team's R&D strength and commercial vision, and look forward to this round of financing helping the company accelerate the global clinical breakthrough of its core products."

Mr. Hu Xubo, Managing Partner of Qiming Venture Partners, stated: "As an early investor in Oricell Therapeutics, we have accompanied and witnessed the company's deep cultivation and steady progress in the CAR-T field: from autologous CAR-T to secretory CAR-T, to a 3-day rapid production process, and the forward-looking layout of in vivo CAR-T. We have seen the company’s continuous advancements in research and development. We are delighted to be part of a process with the potential to generate globally groundbreaking technologies and products."

About Oricell Therapeutics

Qrigincell Therapeutics is a clinical-stage biotechnology company committed to becoming a pioneer in innovative, globally leading tumor immunotherapies. The company currently focuses on developing innovative cell therapies to address unmet medical needs in the global fields of oncology and immunology. Leveraging proprietary expertise from its self-developed Ori®Ab antibody screening and engineering platform, Ori®Armoring structural platform, and OnGo(Fast)CMC, Qrigincell Therapeutics has developed multiple product pipelines for treating solid tumors and hematological malignancies. These have demonstrated favorable safety and efficacy in exploratory clinical studies. Relevant clinical research data have been presented at international conferences such as the 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH, 2025 AACR, 2025 ASCO, and 2025 EHA, as well as in the international academic journal *The Lancet Haematology*. Qrigincell Therapeutics is dedicated to advancing the field of cell therapy through innovative technologies, bringing new hope to patients.

About Beijing Medical and Health Industry Investment Fund

The Beijing Medical and Health Industry Investment Fund is managed by Beijing Shunxi Private Equity Fund Management Co., Ltd. ("Shunxi Fund"). Shunxi Fund is a full-life-cycle investment platform under Beijing State-owned Capital Management Co., Ltd. (Beijing Guoguan), focusing on strategic emerging industry investments. Since its establishment, Shunxi Fund has evolved from being positioned as Beijing Guoguan's venture capital platform for "early-stage, small-scale, technology-focused, and Beijing-oriented" investments into a comprehensive full-life-cycle investment platform. By establishing strong cooperative relationships with multiple universities and research institutions, new R&D organizations, municipal and district-level state-owned capital funds, market-driven GP partners, leading enterprises in industrial chains, and relevant government departments, it has continuously built a multi-dimensional collaborative support system. This has enabled the accumulation of unique advantages, diversified channels for high-quality project resources, and post-investment empowerment capabilities.

About Qiming Venture Partners

Qiming Venture Partners, established in 2006, has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong (China), Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages 11 US dollar funds and 7 RMB funds, with total managed assets reaching 9.4 billion US dollars. Since its inception, it has focused on investing in outstanding enterprises in the early and growth stages of the Technology and Consumer (T&C) and Healthcare industries.

About Qatar Investment Authority

Qatar Investment Authority (“QIA”) is the sovereign wealth fund of the State of Qatar. Established in 2005, QIA is responsible for investing and managing the state reserve fund. As one of the largest and most active sovereign wealth funds globally, QIA invests in a variety of asset classes and regions. It partners with leading institutions worldwide to build a globally diversified investment portfolio with a long-term outlook, aiming to achieve sustainable returns and contribute to the prosperity of the State of Qatar.

About Yizhuang Guotou

Beijing Yizhuang International Investment Development Co., Ltd. (hereinafter referred to as "Yizhuang Guotou") is a state-owned capital investment and operation company with the mission of promoting Beijing's industrial development and technological innovation. Yizhuang Guotou closely focuses on its functional positioning as a "professional, market-oriented, and value-driven industrial empowerment investment platform," concentrating on four major industries: next-generation information technology, biotechnology and healthcare, new energy intelligent vehicles, robotics, and intelligent manufacturing. It deeply cultivates four core businesses: industrial investment, fund management, technology finance, and innovation base. It actively supports the construction of Beijing’s “four centers” functions. As of the end of September 2025, Yizhuang Guotou's total assets exceeded 140 billion yuan, with over 280 investment projects under management. It manages more than 90 funds, with paid-in capital contributions exceeding 60 billion yuan, and the total scale of the funds surpassing one trillion yuan.

About Licheng Investment

Lichi Investment, established in 2021, is a professional institution focusing on early-stage investments in the field of innovative biopharmaceuticals. With the aim of meeting rigid clinical needs, Lichi Investment looks forward to partnering with enterprises and entrepreneurs who own independent intellectual property rights and globally leading technologies, growing together with them to develop products and solutions that can achieve clinical benefits, for the well-being of patients and society.

About Ruifeng Capital

Ruifeng Capital is a private equity investment institution under Fortune Harbour, a licensed entity by the Hong Kong Securities and Futures Commission. It focuses on outstanding enterprises in the Greater China region, ranging from growth-stage to mid-market stage. By concentrating on core sectors and adhering to the principle of prioritizing enterprise quality and empowering through support for management teams, Ruifeng Capital empowers companies with capital and strategic resources, accompanying them in achieving sustainable growth and long-term value enhancement.